12 August 2021 in Journal of Surgical Research
3 November 2023 in Canadian Journal of Respiratory Therapy
Background: Primary studies have demonstrated the effectiveness of noninvasive respiratory supports, including noninvasive positive pressure ventilation (NIPPV) and high flow nasal cannula (HFNC), for improving oxygenation and ventilation in patients with interstitial lung diseases (ILDs) and acute respiratory failure (ARF). These studies have not been synthesized and are not included in current practice guidelines. This systematic review with meta-analysis synthesizes studies that compared the effectiveness of NIPPV, HFNC and conventional oxygen therapy (COT) for improving oxygenation and ventilation in ILD patients with ARF. Methods: MEDLINE, EMBASE and the Cochrane Library searches were conducted from inception to August 2023. An additional search of relevant primary literature and review articles was also performed. A random effects model was used to estimate the PF ratio (ratio of arterial oxygen partial pressure to fractional inspired oxygen), PaCO 2 (partial pressure of carbon dioxide), mortality, intubation rate and hospital length of stay. Results: Ten studies were included in the systematic review and meta-analysis. Noninvasive respiratory supports demonstrated a significant improvement in PF ratio compared to conventional oxygen therapy (COT); the mean difference was 55.92 (95% CI [18.85-92.99]; p =0.003). Compared to HFNC, there was a significant increase in PF ratio in NIPPV (mean difference 0.45; 95% CI [0.12–0.79]; p =0.008). There were no mortality and intubation rate benefits when comparing NIPPV and HFNC; the mean difference was 1.1; 95% CI [0.83-1.44]; p =0.51 and 1.86; 95% CI [0.42-8.33]; p =0.42, respectively. In addition, there was a significant decrease in hospital length of stay in HFNC compared to NIPPV (mean difference 9.27; 95% Cl [1.45 – 17.1]; p =0.02). Conclusions: Noninvasive respiratory supports might be an alternative modality in ILDs with ARF. NIPPV demonstrated a potential to improve the PF ratio compared to HFNC. There was no evidence to support the benefit of NIPPV or HFNC in terms of mortality and intubation rate.
22 March 2026 in Clinical Critical Care
TPTanudchaporn Porntewabuncha
Tanudchaporn Porntewabuncha
Tranexamic acid (TXA), a synthetic lysine analogue that stabilizes fibrin clots against premature degradation, has become a cornerstone in the management of acute hemorrhage. Its application has expanded from well-established indications like trauma and postpartum hemorrhage to a variety of other clinical scenarios. However, this widespread use is accompanied by a complex evidence base, with significant variations in dosing, timing, and administration routes, and a growing recognition of conditions where TXA's risk may outweigh its benefit. This narrative review aims to consolidate and critically appraise the evidence from landmark clinical trials and major international guidelines. We explore the established and emerging indications for TXA, delve into its nuanced safety profile, and highlight the critical importance of timely administration. Ultimately, this review provides clinicians with a practical, evidence-based synthesis to guide the safe and effective use of TXA in resuscitation and the management of bleeding.
25 June 2026 in Respiratory Medicine